| Pay vs Performance Disclosure - USD ($) | 12 Months Ended |
| Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
| Pay vs Performance Disclosure | | | | |
| Pay vs Performance Disclosure, Table | Average Summary Compensation Table Total for Non-PEO NEOs ($) (1) Average Compensation Actually Paid to Non-PEO NEOs ($) (2) Value of Initial Fixed $100 Investment Based On: Year Summary Compensation Table Total for PEO ($) (1) Compensation Actually Paid to PEO ($) (2) Total Shareholder Return ($) (3) Peer Group Total Shareholder Return ($) (3) GAAP Net Income/ (Loss) ($ in thousands) (4) Total Revenues ($ in thousands) (5) 2023 15,341,235 (2,503,427) 4,231,034 208,193 82.40 118.87 414,832 3,834,204 2022 17,325,618 26,315,005 5,035,509 7,254,180 106.72 113.65 (224,060) 3,659,374 2021 15,679,311 4,921,238 4,544,613 2,655,063 85.34 126.45 (329,668) 3,094,238 2020 12,573,300 19,597,659 4,091,303 6,154,655 110.56 126.42 238,616 2,363,567 | | | |
| Company Selected Measure Name | total revenues | | | |
| Named Executive Officers, Footnote | For each fiscal year, represents amount reported for our principal executive officer (PEO) and average amount reported for our non-PEO NEOs, in each case in the Total column of the Summary Compensation Table. Our PEO and our non-PEO NEOs for each of the applicable years were as follows: Year PEO Non-PEO NEOs 2023 Bruce C. Cozadd Renee Gala, Patricia Carr, Robert Iannone, Neena Patil, Daniel N. Swisher, Jr. and Kim Sablich 2022 Bruce C. Cozadd Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Kim Sablich 2021 Bruce C. Cozadd Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Chris Tovey 2020 Bruce C. Cozadd Daniel N. Swisher, Jr., Renee Gala, Robert Iannone and Kim Sablich | | | |
| Peer Group Issuers, Footnote | For the relevant fiscal year, represents the cumulative Total Shareholder Return of our ordinary shares and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any. | | | |
| PEO Total Compensation Amount | $ 15,341,235 | $ 17,325,618 | $ 15,679,311 | $ 12,573,300 |
| PEO Actually Paid Compensation Amount | $ (2,503,427) | 26,315,005 | 4,921,238 | 19,597,659 |
| Adjustment To PEO Compensation, Footnote | Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO NEOs for the relevant fiscal year. Compensation Actually Paid represents the amount reported in the Total column of the Summary Compensation Table for the applicable fiscal year, adjusted as shown below. For the purposes of the below adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB ASC 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. Fair value or change in fair value, as applicable, of equity awards in the Compensation Actually Paid columns was determined as follows: (i) for RSUs, the closing price of our ordinary shares on the applicable fiscal year-end date, or, in the case of vesting RSUs, the closing price of our ordinary shares on the applicable vesting date; (ii) for PSUs, the closing fair value of the awards using a Monte-Carlo simulation method, multiplied by a factor reflecting achievement of the probable outcome of the cumulative performance objective as of the measurement date; and (iii) for stock options, the closing fair value of the stock options based on a Black-Scholes option pricing model on the applicable fiscal year-end date, or, in the case of vesting stock options, the closing fair value on the applicable vesting date. Details of the adjustments made to the Summary Compensation Table are as follows: 2023 Adjustments PEO Average Non-PEO NEOs Total compensation as reported in the Summary Compensation Table (SCT) 15,341,235 4,231,034 (Deduct): Grant date fair value of awards as reported in the Stock Awards column in the SCT for current fiscal year (FY) (12,896,545) (3,127,460) Add: ASC 718 fair value of awards granted during applicable FY that remain unvested as of current FY-end, determined as of applicable FY-end 8,386,732 2,038,949 Add: ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FY-end, determined based on change in ASC 718 fair value from prior FY-end to current FY-end (11,724,562) (2,569,486) Add: ASC 718 fair value of awards granted during prior FYs that vested during current FY, determined based on change in ASC 718 fair value from prior FY-end to vesting date (1,610,287) (364,844) Total Adjustments (17,844,662) (4,022,841) Compensation Actually Paid (2,503,427) 208,193 | | | |
| Non-PEO NEO Average Total Compensation Amount | $ 4,231,034 | 5,035,509 | 4,544,613 | 4,091,303 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 208,193 | 7,254,180 | 2,655,063 | 6,154,655 |
| Adjustment to Non-PEO NEO Compensation Footnote | Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO NEOs for the relevant fiscal year. Compensation Actually Paid represents the amount reported in the Total column of the Summary Compensation Table for the applicable fiscal year, adjusted as shown below. For the purposes of the below adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB ASC 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. Fair value or change in fair value, as applicable, of equity awards in the Compensation Actually Paid columns was determined as follows: (i) for RSUs, the closing price of our ordinary shares on the applicable fiscal year-end date, or, in the case of vesting RSUs, the closing price of our ordinary shares on the applicable vesting date; (ii) for PSUs, the closing fair value of the awards using a Monte-Carlo simulation method, multiplied by a factor reflecting achievement of the probable outcome of the cumulative performance objective as of the measurement date; and (iii) for stock options, the closing fair value of the stock options based on a Black-Scholes option pricing model on the applicable fiscal year-end date, or, in the case of vesting stock options, the closing fair value on the applicable vesting date. Details of the adjustments made to the Summary Compensation Table are as follows: 2023 Adjustments PEO Average Non-PEO NEOs Total compensation as reported in the Summary Compensation Table (SCT) 15,341,235 4,231,034 (Deduct): Grant date fair value of awards as reported in the Stock Awards column in the SCT for current fiscal year (FY) (12,896,545) (3,127,460) Add: ASC 718 fair value of awards granted during applicable FY that remain unvested as of current FY-end, determined as of applicable FY-end 8,386,732 2,038,949 Add: ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FY-end, determined based on change in ASC 718 fair value from prior FY-end to current FY-end (11,724,562) (2,569,486) Add: ASC 718 fair value of awards granted during prior FYs that vested during current FY, determined based on change in ASC 718 fair value from prior FY-end to vesting date (1,610,287) (364,844) Total Adjustments (17,844,662) (4,022,841) Compensation Actually Paid (2,503,427) 208,193 | | | |
| Compensation Actually Paid vs. Total Shareholder Return | | | | |
| Compensation Actually Paid vs. Net Income | | | | |
| Compensation Actually Paid vs. Company Selected Measure | | | | |
| Total Shareholder Return Vs Peer Group | | | | |
| Tabular List, Table | Total Revenues • Revenue (product- / therapeutic area-specific) • Non-GAAP Adjusted Operating Margin • Relative TSR • Pipeline Progression • Regulatory Advancement | | | |
| Total Shareholder Return Amount | $ 82.40 | 106.72 | 85.34 | 110.56 |
| Peer Group Total Shareholder Return Amount | 118.87 | 113.65 | 126.45 | 126.42 |
| Net Income (Loss) | $ 414,832,000 | $ (224,060,000) | $ (329,668,000) | $ 238,616,000 |
| Company Selected Measure Amount | 3,834,204,000 | 3,659,374,000 | 3,094,238,000 | 2,363,567,000 |
| PEO Name | Bruce C. Cozadd | Bruce C. Cozadd | Bruce C. Cozadd | Bruce C. Cozadd |
| Additional 402(v) Disclosure | The amounts represent the GAAP net income (loss) as reported in our audited financial statements for the applicable fiscal year. As required by Item 402(v) of Regulation S-K, we have determined that the Company-Selected Measure is total revenues as reported in our audited financial statements for the applicable fiscal year. | | | |
| Measure:: 1 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Total Revenues | | | |
| Measure:: 2 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Revenue (product- / therapeutic area-specific) | | | |
| Measure:: 3 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Non-GAAP Adjusted Operating Margin | | | |
| Measure:: 4 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Relative TSR | | | |
| Measure:: 5 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Pipeline Progression | | | |
| Measure:: 6 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Regulatory Advancement | | | |
| PEO [Member] | Equity Awards Adjustments | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (17,844,662) | | | |
| PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (12,896,545) | | | |
| PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 8,386,732 | | | |
| PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (1,610,287) | | | |
| PEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (11,724,562) | | | |
| Non-PEO NEO [Member] | Equity Awards Adjustments | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (4,022,841) | | | |
| Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (3,127,460) | | | |
| Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 2,038,949 | | | |
| Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (364,844) | | | |
| Non-PEO NEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (2,569,486) | | | |
